BioCentury
ARTICLE | Company News

Gilead seeking U.S. approval of idelalisb for NHL

September 12, 2013 12:25 AM UTC

Gilead Sciences Inc. (NASDAQ:GILD) submitted an NDA to FDA for idelalisib to treat indolent non-Hodgkin's lymphoma (NHL). The application is based on data from the Phase II Study 101-09. Gilead reported interim data from the trial in June showing idelalisib led to an overall response rate (ORR) of 53.6%. The company gained the small molecule inhibitor of phosphoinositide 3-kinase (PI3K) delta through its 2011 acquisition of Calistoga Pharmaceuticals Inc. (see BioCentury Extra, June 17). ...